Tumor Immunotherapy
06:51Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
16:56Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
08:06Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
05:01Multiplexed Immunofluorescence Imaging to Analyze Immunotherapy-Resistant T Cell Subpopulations
08:40Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jan 20, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Asli Özkan1, Nienke A de Glas1,2, Johanneke E A Portielje1
1Department of Medical Oncology, Department of Medical Oncology, Leiden University Medical Center, Leiden 2333 ZA, The Netherlands.
As the global population ages, understanding immunosenescence (age-related immune decline) is crucial for optimizing cancer immunotherapy. This research explores its impact on treatment response and adverse events in older patients.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: